Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Complete Survey Give us your thoughts and feedback!
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
First, What Exactly Are We Researching Here
avoid repeated freezethaw cycles to maintain structural integrity and assay performance
US$ 28.52
US$ 21.27
US$ 21.08
US$ 25.52
US$ 20.07
US$ 25.92
